• Bloomberg

  • SHARE

Chugai Pharmaceutical Co., the Japanese unit of Roche Holding AG, said Tuesday its first-half profit fell 10 percent on lower sales of the antiviral drug Tamiflu and after the company ended a partnership with Sanofi-Aventis SA.

Net profit dropped to about ¥18.9 billion from ¥21.1 billion a year earlier, Chugai Pharma said in a statement to the Tokyo Stock Exchange. The result exceeded an April forecast of ¥15.5 billion, while sales retreated to ¥145.9 billion, missing a forecast by 2.8 percent.

Unable to view this article?

This could be due to a conflict with your ad-blocking or security software.

Please add japantimes.co.jp and piano.io to your list of allowed sites.

If this does not resolve the issue or you are unable to add the domains to your allowlist, please see out this support page.

We humbly apologize for the inconvenience.

In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.

SUBSCRIBE NOW